1 |
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 23, pp. 2204-2213 (2012)
|
|
BASE
|
|
Show details
|
|
2 |
Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits.
|
|
|
|
In: Symplectic Elements at Oxford ; Europe PubMed Central ; PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) ; Web of Science (Lite) (http://apps.webofknowledge.com/summary.do) ; Scopus (http://www.scopus.com/home.url) ; CrossRef (2005)
|
|
BASE
|
|
Show details
|
|
3 |
Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits
|
|
|
|
In: American Journal of Human Genetics , 76 (6) pp. 1074-1080. (2005) (2005)
|
|
BASE
|
|
Show details
|
|
4 |
Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits
|
|
|
|
In: AM J HUM GENET , 76 (6) 1074 - 1080. (2005) (2005)
|
|
BASE
|
|
Show details
|
|
5 |
Identification of FOXP2 Truncation as a novel cause of developmental speech and language deficits
|
|
|
|
In: American Journal of Human Genetics , 76 (6) pp.1074 - 1080. (2005) (2005)
|
|
BASE
|
|
Show details
|
|
6 |
40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.
|
|
|
|
BASE
|
|
Show details
|
|
|
|